Zogenix (ZGNX) Zohydro ER Fails to Win FDA Panel Backing
- Wall Street opens higher as rising oil boosts energy stocks
- UPDATE: Tesla (TSLA) Tops Q1 EPS by 3c; Plans Q2 Production of ~20,000 Vehicles
- Alibaba (BABA) Misses Q4 EPS, GMV Rises 24%
- Oil rallies as Canada fire, Libya violence unleash supply fears
- Pre-Open Stock Movers 05/05: (SYNC) (AAWW) (ZNGA) Higher; (FRSH) (RRTS) (FIT) Lower (more...)
Zogenix (Nasdaq: ZGNX) Zohydro ER fails to win FDA panel backing.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KemPharm (KMPH) Halted Ahead of FDA Panel Review of Apadaz NDA
- Dycom Industries (DY) Amends Complaint Against Quanta Services (PWR) Over Breach Of Contract
- Valeant's (VRX) Bausch + Lomb and IBM (IBM) Enter New Collaboration
Create E-mail Alert Related CategoriesCorporate News, FDA, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!